Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in Severe Fibromyalgia Syndrome
NCT05643794Phase 2Completed
- Sponsor
- UCB
- Start
- Dec 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rozanolixizumab in fibromyalgia (FM), sponsored by UCB. Started Dec 2022; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT05643794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643794.